Role of Navayasa Lauha Vati and Katuki Vati along with lifestyle modifications in the management of nonalcoholic fatty liver disease(Yakrita Vikara) associated with obesity.

Efficacy of Navayasa Lauha Vati and Katuki Vati along with lifestyle modifications in the management of nonalcoholic fatty liver disease(Yakrita Vikara) associated with obesity – A single arm open labelled clinical study.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051384

Enrollment

Registered

2023-04-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E713- Disorders of fatty-acid metabolism

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age group - 25-60 years.Previously diagnosed and newly diagnosed case of NAFLD (fatty liver grade I or II )confirmed by ultrasonography along with obesity (class1or 2) with or without symptoms of NAFLD (abdominal pain, abdominal heaviness, fatigue, nausea, vomiting, constipation, abdominal distension and burning sensation in abdomen). Patients willing to participate in the clinical trial

Exclusion criteria

Exclusion criteria: Age below 25 years and above 60 years.Patients of NAFLD without obesity.Patients having class III obesity.Patients with uncontrolled DM, (RBS >200mg/dl/), stage II HTN (160/100 mm Hg), Overt hypothyroidism (TSH 10Miu/L) in spite of taking medication.Patients suffering from Hepatitis, Cirrhosis of liver, Ascites, Chronic kidney diseases.Patients suffering from AIDS, Tuberculosis and other infectious diseases, Malignancies, Major psychiatric problems or any other serious illnesses.Pregnant, lactating women. Patient on long term medication (Hepatotoxic medication like NSAID, Rifampicin, steroid) Patients consuming Alcohol or other narcotic substance.

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of NAFLD.Timepoint: 0 day and after 8 weeks	—

Secondary

Measure	Time frame
To improve quality of life in patients of NAFLD associated with obesity assessed by CLDQ.Timepoint: on 0 day and after 8 weeks.	—

Countries

India

Contacts

Public ContactManisha chaudhary

ITRA, Jamnagar, Gujarat

mandipgoyal22@gmail.com9427572306

Outcome results